AU1549088A - Use of aldose reductase inhibitors to enhance insulin sensitivity in diabetes - Google Patents
Use of aldose reductase inhibitors to enhance insulin sensitivity in diabetesInfo
- Publication number
- AU1549088A AU1549088A AU15490/88A AU1549088A AU1549088A AU 1549088 A AU1549088 A AU 1549088A AU 15490/88 A AU15490/88 A AU 15490/88A AU 1549088 A AU1549088 A AU 1549088A AU 1549088 A AU1549088 A AU 1549088A
- Authority
- AU
- Australia
- Prior art keywords
- insulin
- diabetes mellitus
- aldose reductase
- type
- diabetes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Description
USE OF ALDOSE REDUCTASE INHIBITORS TO ENHANCE INSULIN SENSITIVITY IN DIABETES MELLITUS
Background of the Invention
The present invention relates to the field of diabetes mellitus therapy. More particularly, this invention relates to the use of compounds having aldose reductase inhibiting activity (hereinafter referred to as "aldose reductase inhibitors") to correct an abnormal metabolic pathway associated with diabetes mellitus, thereby enhancing and/or restoring insulin sensitivity.
The term "diabetes mellitus" is used to describe chronic hyperglycemia and the side effects of glucose toxicity. There are two general classifications of diabetes mellitus: (1) insulin-dependent (Type I), and (2) noninsul in-dependent (Type II). The present invention is directed to the treatment of both Type I and Type II diabetes mellitus, particularly Type II.
The above-cited classifications of diabetes mellitus are based on the role insulin plays in the disease state. Type I diabetes mellitus is generally attributable to an insulin deficiency. In contrast, it is clear that simple insulin deficiency cannot entirely account for the diabetic syndrome seen in Type II diabetes mellitus. This conclusion is supported by the following observations: (1) in many Type II diabetics, insulin deficiency is not present; and (2) even in Type II diabetics who have impaired insulin secretion leading to an insulin deficiency, insulin resistance can be demonstrated to be responsible for their hyperglycemic state. Reference is made to the following articles for further background in this regard: Reaven et al., "Nonketotic diabetes mellitus: insulin deficiency or insulin resistance?", American Journal of Medicine, Vol. 60, page 80 (1976); Alford et al., "The significance and interpretation of mildly abnormal oral glucose tolerance," Diabetoloqia, Vol. 7, page 173 (1971); and DeFronzo et al., "Insulin sensitivity and insulin binding to monocytes in maturity-onset diabetes," Journal of Clinical Investigation, Vol. 63, page 939 (1979).
It is known that the insulin resistance associated with Type II diabetes mellitus patients and consequent hyperglycemia can be partially reversed with frequent insulin injections. Moreover, it is known that insulin receptor function in Type II diabetes mellitus patients can be modified by sustained, rigorous caloric and/or carbohydrate restriction, oral hypoglycemic drug therapy, insulin injections, and/or physical exercise which results in weight Toss. With these therapeutic approaches, taken either alone or in combination (i.e., diet, exercise, insulin, and/or oral hypoglycemics), the net overall effect is to lower blood glucose over a sustained time. This effect is called "induced hypoglycemia." The following articles may be referred to for further background in connection with known therapeutic methods of inducing hypoglycemia, and the resulting modification of insulin receptor function: Savag et al., "Diet induced improvement of abnormalities in insulin and glucagon secretion and in insulin receptor binding in diabetes mellitus," Diabetes Care, Vol. 5, pages 999-1007 (1979); Beck-Nielsen et al., "Normalization of the insulin sensitivity and the cellular insulin binding during treatment of obese patients following treatment with glibencl amide," Acta Endocrinology, Vol. 90, pages 103-112 (1979); Beck-Nielsen et al., "Increased insulin sensitivity and cellular insulin binding in obese diabetes following treatment with glibenclamide," Acta Endocrinology, Vol. 90, pages 451-462 (1979); Rizkalla et al., "Insulin receptor changes in Type II diabetes after short-term insulin treatment," Horm. Metabol. Res., Vol. 17, pages 512-517 (1985); Scarlett et al., "Insulin treatment reverses the insulin resistance of Type II diabetes mellitus," Diabetes Care, Vol. 5, pages 353-363 (1982); and Selig, "Hypoglycemia during prolonged exercise in normal men," Endocrinology, Vol. 1983, pages 209-212 (1983). While applicant is not bound by any theory, it is believed that inducing hypoglycemia will, in time, increase insulin sensitivity in
Type II diabetes mellitus. It follows that frequent episodes of hyperglycemia in adults induced, for example, by a high calorie diet and lack of exercise, will eventually diminish insulin sensitivity and induce Type II diabetes mellitus. The aforementioned chronic process may be described as an insidious change in the glucose "set point"
induced by improper life style and aging. The biochemical mechanism underlying a loss of insulin sensitivity and concomitant changes in glucose metabolism in connection with Type II diabetes mellitus is believed to involve the energetically expensive enzymatic conversion of the aldose sugar, glucose, to sorbitol at the cost of NADPH. This loss of NADPH co-factor substantially suppresses the very dynamic reduction of oxidized glutathione into reduced glutathione. Reduced glutathione is believed to be involved in maintaining normal insulin receptor function at the target cells. It has been previously demonstrated that insulin release in response to glucose is related to the redox state of islet cell thiols, and that reduced glutathione enhances the capacity of glucose to induce insulin release. See Hallman et al., "Stimulation of insulin release by thiols," Biochem. Biophys. Acta, Vol. 392, pages 101-109 (1975); and Ammon et al., "Cysteine analogues potentiate glucose-induced insulin release in vitro," Diabetes, Vol. 35, pages 1390-1396 (1986), respectively. It has also been suggested that metabolic changes in cellular glutathione in diabetes mellitus cause other reversible thiol-disulfide regulated metabolic changes which result in a net increase in cellular gluconeogenesis. See Ziegler, "Role of reversible oxidation-reduction of enzyme thiol-disulfide in metabolic regulation," Annu. Rev. Biochem., Vol. 54, pages 305-329 (1984).
Summary of the Invention
The present invention is directed to enhancing insulin sensitivity at or within target tissues by administering one or more aldose reductase inhibitors to patients who are either afflicted with diabetes mellitus or predisposed to acquiring this disease. An appropriate aldose rethictase inhibitor regimen will prevent and/or reverse loss of insulin sensitivity. This treatment with aldose reductase inhibitors results in a gradual decrease in insulin resistance by enhancing normal insulin receptor function at the target cells. This positive effect on insulin receptor function is believed to be the result of normalization of the redox state of the affected cells (i.e., normalization of the
conversion of intracellular oxidized glutathione to reduced glutathione); more specifically, the enhancement of insulin receptor sensitivity is believed to result directly from increased cellular levels of reduced glutathione.
While applicant is not bound by any theory, it is believed that the above-cited normalization of glutathione metabolism is the indirect result of interruption of an abnormal metabolic pathway by aldose reductase inhibitors. More particularly, diabetes mellitus is believed to involve an abnormal metabolic pathway wherein the aldose sugar, glucose, is converted to sorbitol at the expense of NADPH. This loss of NADPH affects the cellular redox state in a manner such that the conversion of oxidized glutathione to reduced glutathione is decreased, thereby decreasing the amount of reduced glutathione available at the insulin receptors. Reduced glutathione either directly or indirectly (e.g., via a transferase) maintains the insulin receptor in a reduced thiol state. An insulin receptor active site must be in a reduced thiol state in order for a mixed disulfide bond or an activated complex to form between insulin and the insulin receptor. Aldose reductase inhibitors prevent the above-described depletion of NADPH and resulting decrease in cellular reduced glutathione levels and thiol reduction potential by inhibiting glucose reducing enzymes, such as aldose reductase and L-hexonate dehydrogenase, and thereby promote the binding of both endogenous and exogenous insulin to insulin receptor sites.
The methods of the present invention are applicable to treatment of both Type I and Type II diabetes mellitus, and to reversal and prevention of Type II diabetes mellitus, and comprise administering a therapeutically effective amount of an aldose reductase inhibitor. The administration of an appropriate aldose reductase inhibitor regimen effectively lowers blood glucose levels in Type I and Type II diabetes mellitus patients by enhancing the action of endogenous and exogenous insulin. As the result of the administration of an appropriate aldose reductase inhibitor regimen to a patient afflicted with Type I diabetes mellitus, the amount of insulin required to maintain a normal blood
glucose level may be reduced. A similar result will be expected in Type II diabetes mellitus patients who are receiving insulin therapy. In Type II patients receiving a combination of insulin and an aldose reductase inhibitor, it may be possible to discontinue insulin use after a relatively short course of therapy (e.g., several weeks) with this combination, and to maintain a normal blood glucose level thereafter using only aldose reductase inhibitor therapy.
The present invention also provides a method of preventing, or at least retarding, the onset of Type II diabetes mellitus in patients who are predisposed to acquiring this disease. A fasting blood glucose level of greater than 140 mg of glucose per deciliter of blood is generally associated with a clinical diagnosis of Type II diabetes mellitus. In contrast, a patient having a fasting blood glucose level of greater than 100 mg per deciliter of blood but less than 140 mg per deciliter is considered to be "hyperglycemic." There is a further class of patients who are not yet diabetic in a clinical sense, but are predisposed to acquiring diabetes. These patients are referred to as "latent" or "chemical" diabetics. In accordance with the present invention, it is possible to retard the progression of the underlying disease state in both patients who are hyperglycemic and patients who may be identified as latent or chemical diabetics, thereby preventing the progression of the disease state to a point at which the patients would be clinically diagnosed as having Type II diabetes mellitus. This prevention or prophylaxis is achieved by enhancing the action of endogenous insulin, as explained above.
Detailed Description of the Invention
The aldose dose reductase inhibitors which may be employed in the present invention comprise any compound having aldose reductase inhibiting activity which is therapeutically effective in enhancing insulin sensitivity, and is safe for use in humans and other mammals. Aldose reductase inhibitors which are particularly suitable for use in the method of the present invention are disclosed in commonly assigned U.S. Patent Nos. 4,537,892; 4,436,745; and 4,438,272. The following patents disclose additional examples of aldose reductase inhibitors which may be used in the present invention: U.S. Patent Nos. 3,821,383;
4,117,230; 4,130,714; and 4,181,728. The entire contents of the abovecited patents are hereby incorporated by reference in the present specification. The following compounds represent particularly preferred aldose reductase inhibitors: a.
7,9-difluoro-2-methylspiro(5H-indeno [1,2-b]pyridin-5,3'-pyrolidine)- 2',5'-dione; b.
7,9-difluoro-2-methylspiro(5H-indeno [1,2-b]pyridin-5,4' imidazolidine)- 2',5,-dione;
c.
2,7-difluoro-4-methylspiro(9H-fluoren-9,4'-imidazolidine)-2',5'dione; d.
7-fluoro-2-methylspiro(5H-indeno[1,2-b]-pyridin-5,4' imidazolidine)-2',5'-dione;
e.
2,7-difluoro-4-methylthiospiro(9H-fluoren-9,4'-imidazolidine)-2',5'-dione; f.
7,9-difluoro-2-methylthιospiro(5H-ideno [1,2-b]pyridin-5,4'- imidazolidine)-2',5'-dione;
2,5,7-trifluoro-4-methylspiro(9H-fluoren-9,4'-imidazolidine)-2',5'-dione; h.
2,5,7-trifluoro-4-methylthiospiro(9H-fluoren-9,4'-imidazolidine)-2',5'-dione;
i.
7-methylthiospiro(5H-ideno[1,2-b]pyridin-5,3'-pyrolidine)-2',5'-dione; j.
2,7-difluorospiro(9H-fluoren-9,4' imidazolidin)-2',5'-dione;
2,7-difluorospiro(9H-fluoren-9,5'-oxazolidine)-2'5'dione;
2,7-difluorospiro(9H-fluoren-9,3'-pyrolidine;)-2',5'-dione;
m.
(S)-6-fluorospiro[chroman-4,4'-imidazolidine]-2',5'dione (also called "SORBINIL®"); n.
N-[[5-(trifluoromethyl)-6-methoxy-1-naphthalenyl]thioxomethyl]-n- methylglycine (also called "TOLRESTAT®"); and
o .
[3-(4-bromo-2-fluorobenzyl)-4-oxo-3H-phthalazin-1-yl]acetic acid (also called "STATIL®"). In accordance with the present invention, patients afflicted with diabetes mellitus and patients predisposed to acquiring diabetes mellitus are treated with one or- more aldose reductase inhibitors in an amount effective to enhance insulin sensitivity (i.e., a "therapeutically effective" amount). The aldose reductase inhibitor(s) may be administered to the patient by means of a variety of dosage forms and routes of administration, as will be readily appreciated by those skilled in the art. Oral administration is generally preferred, but topical administration and administration by injection may be found preferable in some instances. Dosage regimens (i.e., amount and frequency) will be determined by the clinician based on factors such as the patient's physical condition and the duration of action of the pharmaceutical composition employed.
Claims (2)
1. A method of enhancing insulin sensitivity in a patient afflicted with diabetes mellitus, which comprises administering a therapeutically effeltive amount of an aldose reductase inhibitor to the patient.
2. A method of preventing or retarding the onset of Type II diabetes mellitus in a patient predisposed to acquiring this condition, which comprises administering a therapeutically effective amount of an aldose reductase inhibitor to the patient.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US2851287A | 1987-03-20 | 1987-03-20 | |
US028512 | 1987-03-20 |
Publications (2)
Publication Number | Publication Date |
---|---|
AU1549088A true AU1549088A (en) | 1988-10-10 |
AU598366B2 AU598366B2 (en) | 1990-06-21 |
Family
ID=21843865
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU15490/88A Ceased AU598366B2 (en) | 1987-03-20 | 1988-03-18 | Use of aldose reductase inhibitors to enhance insulin sensitivity in diabetes |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP0306525A4 (en) |
JP (1) | JPH01503460A (en) |
KR (1) | KR890700346A (en) |
AU (1) | AU598366B2 (en) |
CA (1) | CA1310269C (en) |
WO (1) | WO1988006887A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW438587B (en) | 1995-06-20 | 2001-06-07 | Takeda Chemical Industries Ltd | A pharmaceutical composition for prophylaxis and treatment of diabetes |
KR100343944B1 (en) * | 2001-02-14 | 2002-07-24 | 주식회사 에이.비.아이 | Composition of L-2-oxothiazolidine-4-carboxylic acid or its saits as non-insulin dependent diabetes therapeutic agent |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4130714A (en) * | 1977-05-23 | 1978-12-19 | Pfizer Inc. | Hydantoin therapeutic agents |
US4147797A (en) * | 1978-08-11 | 1979-04-03 | Pfizer Inc. | Spiro-furanohydantoin derivatives |
US4251258A (en) * | 1978-09-29 | 1981-02-17 | Monsanto Company | N-(Substituted carbonyl) derivatives of N-phosphinylmethylglycinates and the herbicidal use thereof |
US4226875A (en) * | 1979-04-02 | 1980-10-07 | Pfizer Inc. | Novel spiro-oxazolidinediones |
US4235911A (en) * | 1979-06-13 | 1980-11-25 | Pfizer Inc. | Hydantoin derivatives |
US4254108A (en) * | 1979-11-08 | 1981-03-03 | Ayerst, Mckenna & Harrison Inc. | Thioxo-1H-benz[de]isoquinoline-2(3H)-acetic acid derivatives and antidiabetic use thereof |
US4436745A (en) * | 1982-04-15 | 1984-03-13 | Alcon Laboratories, Inc. | Method of inhibiting aldose reductase activity |
US4438272A (en) * | 1982-04-15 | 1984-03-20 | Alcon Laboratories, Inc. | Spiro-(fluoren-9,4'-imidazolidine)-2',5'-diones |
US4430337A (en) * | 1982-06-23 | 1984-02-07 | Pfizer Inc. | Alicyclic substituted oxazolidine-2,4-diones having hypoglycemic activity |
US4537892A (en) * | 1983-09-14 | 1985-08-27 | Alcon Laboratories, Inc. | Spiro-tricyclicaromatic succinimide derivatives as inhibitors of aldose reductase |
US4864028A (en) * | 1983-09-14 | 1989-09-05 | Alcon Laboratories, Inc. | Spiro-tricyclicaromatic succinimide derivatives |
US4600717A (en) * | 1984-04-11 | 1986-07-15 | Alcon Laboratories, Inc. | Aldose reductase inhibitors useful in ophthalmic wound healing |
US4609663A (en) * | 1984-09-11 | 1986-09-02 | Alcon Laboratories, Inc. | Aldose reductase inhibitors useful in glaucoma therapy |
JPS6178725A (en) * | 1984-09-20 | 1986-04-22 | アメリカン・ホーム・プロダクツ・コーポレイシヨン | Stabilized tolrestat rotation isomer composition |
US4604406A (en) * | 1984-11-16 | 1986-08-05 | Ayerst, Mckenna & Harrison, Inc. | N-[6-methoxy-5-(perfluoroalkyl)-1-naphtholyl]-N-methylglycines and their thionaphthoyl analogs |
US4575507A (en) * | 1985-05-29 | 1986-03-11 | Pfizer Inc. | Spiro-imidazolidines as aldose reductase inhibitors and their pharmaceutical use |
-
1988
- 1988-03-18 CA CA000561908A patent/CA1310269C/en not_active Expired - Fee Related
- 1988-03-18 WO PCT/US1988/000814 patent/WO1988006887A1/en not_active Application Discontinuation
- 1988-03-18 EP EP19880903550 patent/EP0306525A4/en not_active Withdrawn
- 1988-03-18 AU AU15490/88A patent/AU598366B2/en not_active Ceased
- 1988-03-18 JP JP63503190A patent/JPH01503460A/en active Pending
- 1988-11-19 KR KR1019880701502A patent/KR890700346A/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
KR890700346A (en) | 1989-04-24 |
AU598366B2 (en) | 1990-06-21 |
EP0306525A4 (en) | 1991-04-24 |
WO1988006887A1 (en) | 1988-09-22 |
EP0306525A1 (en) | 1989-03-15 |
CA1310269C (en) | 1992-11-17 |
JPH01503460A (en) | 1989-11-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Brunzell et al. | Effect of a fat free, high carbohydrate diet on diabetic subjects with fasting hyperglycemia | |
US6207714B1 (en) | Methods and pharmaceutical preparations for improving glucose metabolism with (−)-hydroxycitric acid | |
Christlieb et al. | Vascular reactivity to angiotensin II and to norepinephrine in diabetic subjects | |
Glaser et al. | Improved beta-cell function after intensive insulin treatment in severe non-insulin-dependent diabetes | |
Johnson et al. | Hypothesis: could excessive fructose intake and uric acid cause type 2 diabetes? | |
Sönksen et al. | Growth hormone and diabetes mellitus: a review of sixty-three years of medical research and a glimpse into the future? | |
Anderson | Effect of carbohydrate restriction and high carbohydrate diets on men with chemical diabetes | |
CA2073873C (en) | Use of 3-guanidinopropionic acid in the treatment and prevention of metabolic disorders | |
KR20010020497A (en) | Therapeutic method for management of diabetes mellitus | |
JP2004155791A (en) | New niddm treatment | |
EP0808164B1 (en) | Use of prolactin modulators and diet for the manufacture of a medicament for the treatment of obesity | |
US5430065A (en) | Therapeutical method for enhancing peripheral glucose utilization in a non-insulin-dependent diabetic patient | |
Lardinois et al. | Glyburide in non-insulin-dependent diabetes: its therapeutic effect in patients with disease poorly controlled by insulin alone | |
Mathieu | The scientific evidence: vildagliptin and the benefits of islet enhancement | |
US6787163B2 (en) | Therapeutic treatment for blood sugar regulation | |
Hansen | The effect of intravenous glucose infusion on the exercise-induced serum growth hormone rise in normals and juvenile diabetics | |
US6492339B1 (en) | Compositions comprising D-chiro inositol and sulfonylureas and methods of treatment thereof | |
AU1549088A (en) | Use of aldose reductase inhibitors to enhance insulin sensitivity in diabetes | |
US20140329844A1 (en) | Method of restoring the incretin effect | |
Niskanen | Insulin treatment in elderly patients with non-insulin-dependent diabetes mellitus: a double-edged sword? | |
US6486127B1 (en) | Compositions comprising D-chiro inositol and lipid lowering compounds and methods of treatment thereof | |
Campbell | The Somogyi phenomenon. A short review | |
Yuan | Effect of glipizide on non-insulin-dependent diabetes mellitus | |
Stambaugh et al. | Effect of diphenylhydantoin on glucose tolerance in patients with hypoglycemia | |
Lahtela | Effect of Long‐Term Anticonvulsant Therapy on Glucose Metabolism in Humans |